| Patient | Florence Griffith Joyner |
|---|---|
| Date of birth | 1989-12-21 |
| Identifiers | MRN HR-ML033-SYN; SSN (made up) 000-33-2648 |
| Document date | 2026-05-05 |
| Author | Celeste Vanterpool, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
EEG and MRI results and epilepsy consultation. [S]
Ms. Griffith Joyner returns two weeks after her first visit. The sleep-deprived EEG two days after that visit showed intermittent left frontal sharp waves and slowing. MRI of the brain six days after the visit, with susceptibility-weighted imaging, shows a single 1.4 cm cavernous malformation in the left orbitofrontal cortex with a hemosiderin rim and an adjacent developmental venous anomaly, and no other lesion. Dr. Mehta-Sorensen of the epilepsy service saw her this morning. She has had no further seizure, spell or headache. She has not driven, showers rather than bathes, and has not swum. The records of her earlier seizure care have been requested and have not arrived. She is not pregnant (negative test at the first visit) and is not planning a pregnancy now. She has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| EEG | Left frontal sharp waves and focal slowing |
| MRI | Single 1.4 cm left orbitofrontal cavernous malformation with a hemosiderin rim; no other lesion on susceptibility-weighted imaging |
| Since the last visit | No seizure; not driving |
| Coordination | Epilepsy consultation today; neurosurgical opinion requested |
| Her questions | Whether this is epilepsy, whether the lesion can be removed, and when she can train and drive |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or weight change |
| Neurological | Negative | No seizures, spells, headache, weakness or change in smell or vision |
| Musculoskeletal | Negative | Muscle aches after the seizure have gone |
| Genitourinary | Negative | Regular periods; not pregnant |
| Psychiatric | Positive | Worried about another seizure in public; PHQ-9 3; no thoughts of self-harm |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Levetiracetam 500 mg oral tablet, one tablet by mouth twice daily | One tablet twice daily | Oral route | 2026-05-05 | active | S |
| Folic acid 0.4 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-05-05 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-05 | Body height | 170 | cm | S |
| 2026-05-05 | Body weight | 61.2 | kg | S |
| 2026-05-05 | Body mass index (BMI) [Ratio] | 21.2 | kg/m2 | S |
| 2026-05-05 | Systolic blood pressure | 110 | mm[Hg] | S |
| 2026-05-05 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-05-05 | Heart rate | 58 | /min | S |
| 2026-05-05 | Respiratory rate | 14 | /min | S |
| 2026-05-05 | Body temperature | 36.6 | Cel | S |
| 2026-05-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-05 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S |
Vital signs recorded on 2026-05-05; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Fit and well; weight 61.2 kg; blood pressure 110/68, pulse 58 |
| Neurological | Alert and oriented; smell intact to coffee in each nostril; cranial nerves, strength, reflexes, sensation, coordination and gait normal |
| Mouth | No tongue or mouth injury |
| Psychiatric | Composed and attentive; asks precise questions |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Generalized tonic-clonic seizure on a flight two and a half weeks ago, in a 36-year-old woman who was observed overnight in hospital elsewhere and has had treatment for seizures in the past, records requested; no antiseizure medication now; normal examination today. Evaluated as a new seizure: EEG and MRI of the brain with susceptibility-weighted imaging ordered, neurology (epilepsy) review booked, and no driving | resolved | confirmed | R56.9 | S — Synthetic presenting problem anchored to her publicly reported seizure on a flight; superseded by the diagnosis at the epilepsy consultation. |
| Focal epilepsy with structural cause: focal to bilateral tonic-clonic seizure from a left orbitofrontal cavernous malformation, with left frontal epileptiform discharges on EEG; epilepsy under the ILAE 2014 practical definition (an unprovoked seizure with a recurrence risk above 60% from an epileptogenic lesion, and earlier seizures by history); synthetic modern detail linked to her publicly reported seizures and the coroner's finding | active | confirmed | G40.209 | S — Synthetic seizure type, EEG and classification; the seizures and the cavernous angioma of the left orbital frontal cerebrum are documented (D). |
| Solitary cerebral cavernous malformation, 1.4 cm, left orbitofrontal cortex, with a hemosiderin rim and an adjacent developmental venous anomaly, no other lesion on susceptibility-weighted imaging (sporadic pattern); no acute hemorrhage | active | confirmed | Q28.3 | S — Synthetic imaging detail; the coroner reported a congenital cavernous angioma of the left orbital frontal cerebrum (D). |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count, electrolytes, glucose, calcium, magnesium, kidney and liver tests, creatine kinase, pregnancy test | At presentation after a seizure | Up to date | All normal at the first visit; pregnancy test negative |
| Imaging | EEG (sleep-deprived) | After a first seizure, as soon as practical | Up to date | Two days after the first visit: left frontal sharp waves and focal slowing |
| Imaging | MRI of the brain, epilepsy protocol with susceptibility-weighted imaging | After a first seizure | Up to date | Six days after the first visit: single left orbitofrontal cavernous malformation with a hemosiderin rim |
| Examination | Seizure classification and diagnosis of epilepsy | When EEG and imaging are available | Completed today | Focal to bilateral tonic-clonic seizure; focal epilepsy with structural cause (ILAE 2014: one unprovoked seizure with recurrence risk above 60%) |
| Referral | Neurology (epilepsy) | Within two weeks of a first seizure | Completed today | Seen this morning; recommendations in the consultation note |
| Referral | Neurosurgical evaluation of an epileptogenic cavernous malformation | When a cavernous malformation causes epilepsy | Ordered | Requested today, within three weeks |
| Medication safety | Antiseizure medication choice for a woman who could become pregnant | At the start of treatment | Completed today | Levetiracetam 500 mg twice daily; valproate avoided; no contraceptive interaction |
| Medication safety | Folic acid | Daily for anyone taking an antiseizure medication who could become pregnant | Completed today | 0.4 mg daily started |
| Self-management | Contraception and pregnancy planning | At the start of treatment and yearly | Completed today | No pregnancy planned; any method is compatible with levetiracetam; plan a pregnancy with the epilepsy team |
| Survey | Mood and behavior on levetiracetam (PHQ-9) | Before starting and at each visit | Completed today | PHQ-9 3 before the first dose |
| Self-management | Driving restriction and the California physician report | From the first seizure until cleared | Up to date | Not driving; the report California requires was sent after the first visit |
| Self-management | Seizure safety: water, heights, sleep and first aid | At diagnosis and each visit | Completed today | Showers only; swimming only with a companion who knows first aid; no climbing or working at height; written seizure action plan |
| Self-management | Nocturnal seizure detection | When seizures may occur in sleep | Ordered | Wrist-worn detection watch ordered |
| Self-management | SUDEP counseling | At diagnosis of epilepsy | Deferred | Not discussed today: the visit was taken up by the diagnosis, the medication and the surgical question. A deviation from the AAN/AES guideline, which calls for the discussion at diagnosis. Corrective action: booked as the first item at the next visit in three weeks |
Goal progress:
Guideline basis: Krumholz A, et al. Evidence-based guideline: Management of an unprovoked first seizure in adults. Neurology 2015;84(16):1705-1713 (PMID 25901057) (2015); Fisher RS, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014;55(4):475-482 (PMID 24730690) (2014); Akers A, et al. Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. Neurosurgery 2017;80(5):665-680 (PMID 28387823) (2017); Harden C, et al. Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors. Neurology 2017;88(17):1674-1680 (PMID 28438841) (2017); Pack AM, et al. Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication: Practice Guideline From the AAN, AES, and SMFM. Neurology 2024;102(11):e209279 (PMID 38748979) (2024); Beniczky S, et al. Automated seizure detection using wearable devices: A clinical practice guideline of the International League Against Epilepsy and the International Federation of Clinical Neurophysiology. Epilepsia 2021;62(3):632-646 (PMID 33666944) (2021); Governor's message returning Senate Bill 357 without signature (physician reporting of disorders characterized by lapses of consciousness remains mandatory under Health and Safety Code section 103900) (2024); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Neurosurgical opinion within three weeks; primary care review in three weeks to check levetiracetam, mood and the surgical plan, and to discuss SUDEP. Call at once for another seizure; call emergency services for a seizure lasting five minutes or more. Next scheduled visit 2026-05-27: three weeks on levetiracetam: mood and side effects, the neurosurgical opinion and surgery date, SUDEP and safety counseling. [S]